



14th December 2020

**CAUTION IN USE COMMUNICATION
IMPORTANT REMINDER
INFORMATION FOR HEALTHCARE PROFESSIONALS**

**THIS IS A REMINDER LETTER OF INFORMATION CONVEYED ON 2ND JUNE 2020
REGARDING CHANGES TO GUIDANCE ON SINEMET[®] TABLET SUBDIVISION AND
TABLET REMOVAL FROM THE BLISTER PACKAGING.**

**COMMUNICATION OF THE INFORMATION BELOW TO PATIENTS WOULD BE
GREATLY APPRECIATED.**

**Sinemet[®] Plus (carbidopa/levodopa) 25mg/100mg Tablets- PA1286/9/4
Sinemet[®] (carbidopa/levodopa) 12.5mg/50mg Tablets - PA1286/9/2**

Dear Healthcare Professional,

Merck Sharp & Dohme Ireland (Human Health) Limited ('MSD'), in agreement with the Health Products Regulatory Authority (HPRA), would like to inform you of the following:

MSD has received a number of complaints from patients in Ireland of Sinemet[®] Plus (carbidopa/levodopa) 25mg/100mg tablets breaking when they were removed from their blister packaging. (Note that Sinemet[®] 12.5mg/50mg tablets are of a similar tablet design, package configuration, and formulation as the 25mg/100mg tablets, so this letter applies to both products.)

In order to ensure that patients take the correct dose of Sinemet[®] Plus 25mg/100mg tablets and Sinemet[®] 12.5mg/50mg, **please advise your patients as follows:**

- The score line on the tablets is **not intended** to subdivide the tablet into two equal doses and it should not be used in that way.
- If the tablet must be subdivided to aid in swallowing, the tablet should be consumed **ONLY IF** the whole dose (all parts of the tablet) can be taken.
- Do not apply too much force when removing the tablet from the blister.
- If the tablet breaks when it is removed from the blister, the tablet should be consumed **ONLY IF** the whole dose can be taken. If it cannot, the pieces of the broken tablet should be discarded and another tablet taken from the blister.
- Administration of a partial dose may result in worsening of symptoms.
- MSD is continuing to work on actions to reduce the incidence of tablet breakage, and the above points are important as an interim measure.



Additionally:

1. For Sinemet[®] Plus 25mg/100mg tablets, MSD updated the Summary of Product Characteristics (SmPC) and Package Leaflet (PL) to reflect the new guidance stated above on September 10th 2020.
2. For Sinemet[®] 12.5mg/50mg tablets, MSD updated the SmPC and PL to reflect the new guidance stated above on 10th September 2020.
3. Instructions regarding the administration of other presentations of Sinemet[®] remain unchanged.
4. Please consult the SmPC prior to prescribing Sinemet. The most up to date SmPCs are available at www.medicines.ie.

We would appreciate if you could please **immediately** ensure that all of your relevant staff are made aware of the details outlined in this letter and that the information is then communicated to your patients.

Call for reporting

Please note that suspected adverse reactions should be reported to the HPRA electronically via the website at www.hpra.ie or email: medsafety@hpra.ie.

The authorised product information for these medicines is available at www.hpra.ie and at www.medicines.ie.

Company contact point

If you have any questions, please contact us at:

MSD, Red Oak North

South County Business Park,

Leopardstown,

Dublin 18,

Telephone: +353 1 299 8700

Medical Information e-mail: medinfo_ireland@merck.com

Yours sincerely,

A handwritten signature in black ink that reads "Ceara Belviso".

Dr. Ceara Belviso
Director of Medical Affairs